Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

A. S. Kubasch; P. Peterlin; T. Cluzeau; K. S. Götze; K. Sockel; R. Teipel; M. Jentzsch; H. Attalah; M. Sebert; F. Chermat; S. Gloaguen; M. Puttrich; M. Cross; M. Schneider; S. Kayser; D. Schipp; A. Giagounidis; I. Tirado-Gonzalez; A. Descot; A. van de Loosdrecht; A. Weigert; K. H. Metzeler; P. Fenaux; H. Medyouf; U. Platzbecker; L. Ades

doi:10.1038/s41375-023-02029-1

Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

A. S. Kubasch
, P. Peterlin
, T. Cluzeau
, K. S. Götze
, K. Sockel
, R. Teipel
, M. Jentzsch
, H. Attalah
, M. Sebert
, F. Chermat
, S. Gloaguen
, M. Puttrich
, M. Cross
, M. Schneider
, S. Kayser
, D. Schipp
, A. Giagounidis
, I. Tirado-Gonzalez
, A. Descot
, A. van de Loosdrecht

A. Weigert, K. H. Metzeler, P. Fenaux, H. Medyouf, U. Platzbecker, L. Ades

Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie

University Hospital Leipzig
German MDS Study Group (D-MDS)
The European Myelodysplastic Neoplasms Cooperative Group (EMSCO)
University Hospital of Nantes
Nice Teaching Hospital
Universitätsklinikum Carl Gustav Carus Dresden
Groupe Francophone des Myélodysplasies
Hôpital Saint-Louis
Technische Universität Dresden
Heidelberg University
German Cancer Research Center
DS-Statistics
Marienkrankenhaus Düsseldorf-Kaiserswerth
Institute for Biomedical Research
Cancer Center Amsterdam
Frankfurt Cancer Institute

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

12 Zitate (Scopus)

Originalsprache	Englisch
Seiten (von - bis)	2309-2313
Seitenumfang	5
Fachzeitschrift	Leukemia
Jahrgang	37
Ausgabenummer	11
DOIs	https://doi.org/10.1038/s41375-023-02029-1
Publikationsstatus	Veröffentlicht - Nov. 2023

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

Zugriff auf Dokument

10.1038/s41375-023-02029-1

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Dieses zitieren

Kubasch, A. S., Peterlin, P., Cluzeau, T., Götze, K. S., Sockel, K., Teipel, R., Jentzsch, M., Attalah, H., Sebert, M., Chermat, F., Gloaguen, S., Puttrich, M., Cross, M., Schneider, M., Kayser, S., Schipp, D., Giagounidis, A., Tirado-Gonzalez, I., Descot, A., ... Ades, L. (2023). Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial. Leukemia, 37(11), 2309-2313. https://doi.org/10.1038/s41375-023-02029-1

@article{87ccf46202d24f4eb2d1d23e115452f0,

title = "Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial",

author = "Kubasch, \{A. S.\} and P. Peterlin and T. Cluzeau and G{\"o}tze, \{K. S.\} and K. Sockel and R. Teipel and M. Jentzsch and H. Attalah and M. Sebert and F. Chermat and S. Gloaguen and M. Puttrich and M. Cross and M. Schneider and S. Kayser and D. Schipp and A. Giagounidis and I. Tirado-Gonzalez and A. Descot and \{van de Loosdrecht\}, A. and A. Weigert and Metzeler, \{K. H.\} and P. Fenaux and H. Medyouf and U. Platzbecker and L. Ades",

note = "Funding Information: The BERGAMO study was partially supported by BerGenBio. Open Access funding enabled and organized by Projekt DEAL. ",

year = "2023",

month = nov,

doi = "10.1038/s41375-023-02029-1",

language = "English",

volume = "37",

pages = "2309--2313",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "11",

}

Kubasch, AS, Peterlin, P, Cluzeau, T, Götze, KS, Sockel, K, Teipel, R, Jentzsch, M, Attalah, H, Sebert, M, Chermat, F, Gloaguen, S, Puttrich, M, Cross, M, Schneider, M, Kayser, S, Schipp, D, Giagounidis, A, Tirado-Gonzalez, I, Descot, A, van de Loosdrecht, A, Weigert, A, Metzeler, KH, Fenaux, P, Medyouf, H, Platzbecker, U & Ades, L 2023, 'Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial', Leukemia, Jg. 37, Nr. 11, S. 2309-2313. https://doi.org/10.1038/s41375-023-02029-1

TY - JOUR

T1 - Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

AU - Kubasch, A. S.

AU - Peterlin, P.

AU - Cluzeau, T.

AU - Götze, K. S.

AU - Sockel, K.

AU - Teipel, R.

AU - Jentzsch, M.

AU - Attalah, H.

AU - Sebert, M.

AU - Chermat, F.

AU - Gloaguen, S.

AU - Puttrich, M.

AU - Cross, M.

AU - Schneider, M.

AU - Kayser, S.

AU - Schipp, D.

AU - Giagounidis, A.

AU - Tirado-Gonzalez, I.

AU - Descot, A.

AU - van de Loosdrecht, A.

AU - Weigert, A.

AU - Metzeler, K. H.

AU - Fenaux, P.

AU - Medyouf, H.

AU - Platzbecker, U.

AU - Ades, L.

N1 - Funding Information: The BERGAMO study was partially supported by BerGenBio. Open Access funding enabled and organized by Projekt DEAL.

PY - 2023/11

Y1 - 2023/11

UR - https://www.scopus.com/pages/publications/85171658935

U2 - 10.1038/s41375-023-02029-1

DO - 10.1038/s41375-023-02029-1

M3 - Article

AN - SCOPUS:85171658935

SN - 0887-6924

VL - 37

SP - 2309

EP - 2313

JO - Leukemia

JF - Leukemia

IS - 11

ER -